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February 15, 2011:887–9Letters to the EditorR$1 Billion to the National Heart,
Lung, and Blood Institute
Economic Stimulus or Bust?
I read with great interest the National Heart, Lung, and Blood Institute
(NHLBI) summary paper by Lauer (1) regarding funding received from
theAmericanRecovery andReinvestmentAct of 2009. I was surprised at
the $10.4 billion that was allocated from the Recovery Act for the
National Institutes of Health. According to Lauer (1), one-tenth of this
money went to theNHLBI.He goes on to explain the particular division
of the money within the NHLBI for 2-year projects. However, the
Recovery Act was touted by the President as needed funding for the
American economy and as a way of creating “shovel ready” jobs within
months to a year. Out of the funds received and that have been spent,
does the NHLBI have a way of tracking each job created from this
spending? What jobs were truly created from immediate funding of
esearch projects (i.e., “shovel ready”)? Who is accountable and
esponsible for honestly and accurately tracking jobs created from
HLBI Recovery Act funds? As with the construction road signs that
dvertise Recovery Act spending at work, will publications that arise
rom this funding be “advertised” or tracked?
As a physician, I support more research and innovation in
edicine. As a taxpayer, the funding received by the National
nstitutes of Health and NHLBI from the Recovery Act, in my
pinion, will do very little to help create meaningful employment
pportunities and economic recovery for the entire nation.
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Reply
Dr. Galani asks a question of increasing interest to the scientific and
policy community: What is the value of government-sponsored biomed-
ical research (1)? Even before the passage of the American Recovery and
Reinvestment Act (ARRA), economists and biomedical scientists pub-
lished data demonstrating that National Institutes of Health (NIH) and
National Heart, Lung, and Blood Institute (NHLBI) funding leads to
economic growth (1,2), peer-reviewed publications in higher-impact
journals (3), and improved public health (4).
To attempt to get some direct answers to this question specif-
cally related to ARRA funding, the NIH is joining forces with the
TAR METRICS (National Science Foundation in the Science
nd Technology in America’s Reinvestment—Measuring the Ef-
ect of Research on Innovation, Competitiveness and Science)working group (5). Working under the auspices of the White
House Office of Science and Technology Policy (OSTP), the
STAR METRICS working group will examine impacts on job
and economic growth, academic productivity (including publica-
tions and citations), and health outcomes.
In the meantime, NIH is already tracking publications. To
date, NHLBI ARRA-funded research has led to 955 publica-
tions, with some appearing in high-impact journals such as
Nature, Science, Circulation, and the Journal of the American
College of Cardiology (6,7).
This question applies to research investment broadly. Industry
struggles with its research and development investments, with eco-
nomic return as the primary measure. Industry focuses on applied
rather than basic, early translational, or comparative effectiveness
research precisely because economic impact is difficult to measure for
these endeavors, and sponsors must be willing to take risks.
The NHLBI makes investments in generation of data and new
knowledge wholly aware that scientific payoffs are variable and delayed.
Knowledge has intangibles evident by their absence. As Henry Adams
said, “A teacher affects eternity. He never can tell where his influence
stops” (8). The same can be said of research: the fact that we don’t know
where it may lead is an argument in its favor, not a criticism.
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